Vigorous intermittent lifestyle physical activity (VILPA), 3-4 minute bursts per day, associated with ~40% reduction of all-cause mortality, cancer and cardiovascular mortality https://t.co/BoGmigjqWl @NatureMedicine@ma_hamer@M_Stamatakis
We are thrilled to share with you that the results of the EMMY trial are published #ESCCongress#EHJ.
EMPAGLIFLOZIN administered immediately post large MI with #PCI improved:
- NT-proBNP levels and
- markers of cardiac structure and function
https://t.co/iJ8NMVAsxo
We have just launched an exciting #OpenAccess Research Topic on #pharmacogenomics and #pharmacogenetics of cardiovascular/neurovascular disorders! 🫀🧠
📆6th July 2022
Interested? Learn more here ➡️ https://t.co/P8iADazP1a
Sirtuin signaling pathway plays a crucial role in aging. I-COMET team is testing hypothesis that SGLT2 inhibitors may act on SIRT gene interaction network and thus have ani-aging effect.
#icometteam#neverfollowalwayslead#precisionmedicine#antiageing
https://t.co/ddO3yYVrfk
I-COMET team is entering a new area of scientific interest to better predict CV outcomes based on complex risk score. Precision medicine based on new biomarkers #ncRNA#micorbiota#proteome#metabolome is future of cardiology and prevention. #icometteam https://t.co/EnpbEDrTz2